Biomedcode Hellas SA

Biomedcode Hellas SA is a highly innovative preclinical CRO specializing in predictive humanized disease models for biologics development. We offer in vivo drug efficacy evaluation using a diverse array of proprietary mouse models carrying humanized targets such as TNF, TNFR1, IL17, IL23A, IL12B, RANKL, TL1A and others. Our models closely recapitulate the pathology and complexity of human diseases, including Rheumatoid Arthritis, Intestinal Inflammation, Interstitial Pulmonary Fibrosis, Systemic Sclerosis, Psoriasis, Osteoporosis, Lupus, Multiple Sclerosis, Cancer and more. We also provide ex vivo platforms for evaluating therapeutics targeting fibrosis and other complex pathways.

Since 2006, we have partnered with over 130 pharmaceutical and biotech companies worldwide, supporting translational preclinical studies that de-risk programs, optimize decision-making, and accelerate IND-enabling studies.

Combining extensive preclinical expertise with scientific consultation, custom solutions and an active R&D program, Biomedcode bridges discovery and clinical translation, helping teams advance innovative biologics with confidence.